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ABSTRACT  
Background Infants <32 weeks’ gestation should not be exposed to topical iodine and its avoidance 
is recommended during pregnancy and breast feeding.  Exposure to contrast media and topical 
iodine are frequently used in many preterm neonates.     
 
Aim To determine whether thyrotropin levels in preterm infants are affected by exposure to 
intrapartum/neonatal topical iodine and/or use of iodinated contrast media. 
 
Design Infants <32 weeks’ gestation were recruited. Maternal and neonatal exposure to iodinated 
contrast media and topical iodine was recorded; levels of thyrotropin and thyroxine were measured 
from blood-spot card on postnatal days 7, 14, 28 and the equivalent of 36 weeks’ gestation. 
 
Results 125 infants were exposed to topical iodine/contrast media and 48 infants were unexposed.  
No infants were treated for hypothyroidism; 3 infants (exposed group) had transient 
hyperthyrotropinaemia.  Mean thyrotropin levels were significantly higher on postnatal days 7, 14 
and 28 in infants exposed to topical iodine prior to caesarean section compared to unexposed 
infants; a relationship which persisted after adjustment. 
 
Conclusions In the context of this study neonatal thyroid dysfunction was seen following exposure to 
iodine via caesarean section but not via exposure to contrast media.   
 
188 words 
  
3 
 
INTRODUCTION 
The iodine requirement for healthy preterm infants is estimated, from balance studies, to be 30-40 
μg/kg/day [1,2].  Newborn infants receive iodine through three main sources: parenteral nutrition, 
enteral nutrition and breast milk.  Most preterm infants are on parenteral nutrition initially, and 
gradually change to enteral nutrition as their clinical condition improves.  The current guideline for 
iodine intake in enteral nutrition for preterm infants is 11-55 μg/kg/day [3]; whereas the current 
recommended iodine intake in parenteral nutrition regimens is 1 μg/kg/day [4].   The iodine content 
of breast milk reflects maternal iodine status, and a small study in Scotland reported mean levels to 
be ~10 μg/dl [5].  A review of several UK manufactured formula brands (e.g. Comfort first infant 
formula, Cow & Gate Plus, Milupa Aptamil First, SMA Gold) found that none provided the 
recommended iodine intake of 90 g/day at birth for term infants [6].  Parenteral nutrition and the 
iodine content of prescribed drugs and red blood cell concentrates together provided only 1-3 
g/iodine/day [5].  Neonates in the UK do not receive supplemental iodine as they are assumed to 
receive sufficient iodine from enteral and parenteral formula and/or breast milk.  This assumption is 
probably incorrect, especially for infants receiving parental nutrition [7].  
In addition to the risk of iodine deficiency, paradoxically, preterm infants are also vulnerable to the 
effects of iodine overload because the Wolff-Chaikoff effect, which blocks the uptake of excess 
iodine by the thyroid gland, does not mature until around 36-40 weeks’ gestation [8].  Neonatal 
overload may occur through neonatal use of iodinated contrast media [9] and/or iodinated skin 
disinfectants [10], if there is maternal exposure via supplements or topical iodine use during 
pregnancy or delivery, and there is additional infant exposure if the mother breast-feeds [11].  A 
major source of neonatal exposure is from maternal exposure from the use of iodine-based skin 
disinfectants prior to caesarean section [12].   
Several studies have confirmed neonatal thyroid dysfunction consequent to exposure to iodinated 
contrast media [13-15], but the results are inconsistent; one study found no evidence [16] of 
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transient hypothyroidism and another a rate of 75% [14].  The consequence of using iodine-based 
skin disinfectants is also variable, with rates of hypothyroidism reported from 0% [17,18], 20% [19], 
25% [10], to 78% [14].  
Recent systematic reviews considered neonatal exposure to iodinated contrast media [20] and to 
topical iodine [21].  Both reviews concluded that the studies appraised were affected by bias but 
nevertheless neonates exposed to iodinated contrast media and topical iodine appeared to be at risk 
of thyroid dysfunction and development of hypothyroidism.  Preterm infants were identified at 
higher risk than term infants.  Presumably in reflection of this inconsistent but scientifically rational 
evidence [22] the 2013-14 edition of the British National Formulary (BNF) for Children [23] states 
that use of topical iodine is contraindicated in neonates <32 weeks’ postmenstrual age and infants 
<1.5kg, and regular use during pregnancy and while breast-feeding should be avoided.  The 
equivalent American publication cautions that as iodine crosses the placenta it thus may cause 
hypothyroidism/goitre in the fetus and newborn [24].  There is no comment about iodinated 
contrast media, as it is not a listed drug.  However, guidance leaflets included with contrast media 
(e.g. Optiray 300-GB TL -05/2009) recommend monitoring thyroid function 6-10 days and 1 month 
after administration because of the risk of hypothyroidism due to iodine overload.   
The aim of this study was to determine whether exposure to topical iodine or contrast media was 
associated with grossly altered thyroid function as reported by the earlier studies [14]. 
METHODS 
Infants <32 weeks’ gestation were recruited between 2007 and 2012 from five neonatal intensive 
care units in the UK (two in Scotland and three in England); our aim was to recruit infants 
consecutively.  The single exclusion criterion was serious congenital anomaly.  Written informed 
consent was obtained from all mothers. The study was approved by Medical Research Ethics Tayside 
Committee (A), 06/S1401/116. 
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This study compared infants categorised as either exposed or unexposed to topical iodine (maternal 
or neonatal use) and/or iodinated contrast media.  Special care was taken by study nurses to record 
maternal exposure to iodine during pregnancy and parturition, dosage and type of neonatal 
exposure to contrast media, and the use of iodine-based skin disinfectants.  Exposure was classified 
as 1) to neonatal contrast media only, 2) to topical iodine prior to caesarean section only, 3) as 
mixed exposure and 4) unexposed.  Exposure was confirmed by cross-checking obstetric and 
neonatal clinical records.  Neonatal exposure data were collected prospectively by staff actively 
involved in the care of neonates and the study; obstetric data were collected retrospectively but the 
majority of mothers delivered in the same hospital as the neonatal unit, and obstetric policy 
regarding iodine use for skin disinfection is standard for all personnel in the unit.  
The main outcome measures were levels of thyrotropin (TSH) and thyroxine (T4) measured on 
postnatal days 7, 14, 28 and at the equivalent of 36 weeks’ gestation.  Heel-prick blood was spotted 
onto filter-paper card and posted immediately to the Neonatal Screening laboratory, Academic 
Medical Centre, Amsterdam.  The Dutch screening program for congenital hypothyroidism is 
primarily based on T4 measurement in filter paper but measurements of TSH and TBG (thyroid 
binding globulin) are also performed.  T4 levels are also expressed as a standard deviation (T4 sd) of 
the daily mean i.e. z score; levels ≤-3.0 are considered abnormal.  Assays were performed according 
to the manufacturer’s protocol: total T4 by fluoro immunoassay (AutoDelfia, Perkin Elmer, Waltham, 
MA) and TSH by an immunometric assay (Brahms, Thermo scientific, Henningsdorf, Germany).  
Analysis of the blood-spot cards within the screening laboratory ensured that all suspect results 
were quickly notified to the neonatal unit and local diagnostic tests and treatment protocols 
instigated.  We classified TSH levels ≥6mU/L as the threshold of suspicion, as this is the lowest level 
of TSH to prompt recall for repeat testing used by a UK newborn screening laboratory for congenital 
hypothyroidism.  Suspect levels were faxed to FLRW, who alerted the appropriate duty neonatal 
consultant.  Hypothyroidism was classified if treatment with Levo-thyroxine was required; 
hyperthyrotropinaemia was classified as levels of TSH between 10.1 and 19.9 mU/L.  
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Clinical and demographic data were recorded from birth for 28 days; although a final blood sample 
was taken at the equivalent of 36 weeks’ gestational age.  Data recorded included: gestation at birth, 
birth weight, birthweight ratio (infant weight standardised to national data), gender; and on 
postnatal day 7, 14 and 28: type and quantity of nutrition; prescribed drug usage, neonatal 
illnesses/conditions, and level of nursing care required (as a proxy of illness severity) [25].   
Mean levels of TSH and T4 were calculated for infants grouped by source of iodine exposure for each 
day of blood sampling (± a day).  (Infants were only sampled once if their day 28 blood was within a 
day of their 36 weeks’ blood.)  Differences in mean levels between the exposed and unexposed 
groups were found using, as appropriate, the t test for unequal variance or Fisher Exact test.  
Univariate general linear models were used to evaluate TSH levels on days 7, 14 and 28 and 
exposure group adjusted for gestational age, level of nursing care required, birthweight ratio, 
gender, and drug usage.  We collected information about the use of dexamethasone, dopamine and 
caffeine as these drugs can inhibit neonatal TSH secretion [26].    The target sample was 200 infants 
which would give 80% power, p=5%, to detect an incidence of hypothyroidism of 25% in the exposed 
group. 
RESULTS 
Of the 173 infants in the study, 125 were exposed to extraneous iodine and 48 were unexposed 
(other than to dietary iodine contained in breast milk or added by manufacturers to formula milk).  
No infant was exposed to topical iodine for neonatal skin antisepsis; the most frequent exposure 
source was neonatal contrast media (Table 1).   
 
Thirteen infants recorded a level of TSH ≥6mU/L at one of the blood sampling days (Table 2); 6% 
(6/95) of infants exposed only to contrast media, 19% (3/16) infants exposed only to maternal 
topical iodine, and 8% (4/48) of the unexposed group (Tables 1 and 2).  Overall the incidence of 
thyroid dysfunction (TSH≥6mU/L) in our exposed cohort was 7.2%, and 8.3% in the unexposed 
cohort.  No infant was diagnosed with hypothyroidism; three infants had transient 
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hyperthyrotropinaemia and all were from the exposed group.  Five infants who had TSH ≥6 mU/L, all 
from the exposed group, had a T4 z score ≤-3.0; the T4 levels in four infants normalised by 36 weeks 
and one infant died.   
Contrast media for verification of central venous catheter position was the most common source of 
iodine exposure (Table 1).  Three types of media were used: Optiray 300, Omnipaque 240/250 and 
Ultravist 300.  Doses ranged from 0.2-1.0ml per application, with a mode of 0.3ml.  One-hundred-
eight infants were exposed to contrast media; Ultravist 300 was the most commonly used (52%), 
followed by Omnipaque 240 (32%), Optiray 300 (15%) and Omnipaque 250 (1%).  Eighty-six infants 
received a single dose of media, 18 infants received two doses of media and 4 infants received 3 
doses of media.  The median day for receipt of the 1st , 2nd and 3rd doses of contrast media were, for 
the mixed exposure group, 3, 57 and 65 days post birth; while for the contrast only exposure group 
the medians were 3, 17 and 21 days respectively.  Twenty-one infants were exposed to topical 
iodine.  The majority of infants received maternal breast milk during the first 28 days postnatal.  
Generally, breast milk provided the majority of the nutritional intake (Table 3).  
Compared to the unexposed infants, infants exposed to iodine via caesarean section had 
significantly higher TSH and T4 levels on postnatal days 7, 14 and 28 (TSH only); although by the 
equivalent of 36 weeks’ gestation, TSH and T4 levels between the groups did not differ (Table 4).  
Regression analyses confirmed the associations between TSH levels on days 7, 14 and 28, and iodine 
exposure from caesarean section; associations which persisted after adjustment for confounding 
factors (Table 5).   
Compared to unexposed infants, the mean gestational age at birth for the infants exposed only to 
contrast media and the mixed exposure group was significantly lower, and this is reflected by lower 
mean birthweights in these groups (Table 3).  There were 6 neonatal deaths, three in the contrast 
media only group and three in the unexposed group. There were no differences in the levels of 
illness experienced by the groups of infants (Supplementary Table 1).  Neonatal dexamethasone and 
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dopamine was used in less than 1.5% of infants: for the exposed group (respectively 1.1% and 1.3%) 
and unexposed group (0.7% and 0%); caffeine (Table 3) was used for 69.3% of the exposed and 
50.0% of the unexposed group.   
The number of infants with missing neonatal blood data was low (range 0-14%), for all exposure 
groups.  By 36 weeks the amount of missing data was higher (range 20-43%) particularly for the 
caesarean section only and mixed exposure groups (Table 4).  We did not monitor missed infants 
and estimate that we recruited 60% of eligible infants (Supplementary Table 2).     
DISCUSSION 
This study aimed to determine whether the incidence of thyroid dysfunction following iodine 
exposure was as high as the 75-78% previously reported [14].   We found an incidence of thyroid 
dysfunction (TSH≥6mU/L) in the exposed group of 7.2%, and 8.3% for the unexposed group.   
Quantitative information about the iodide content of contrast media is sparse.  Iodinated contrast 
media contain variable but large amounts of bound iodide (biologically inactive), which liberate 
variable amounts of (biologically active) free iodide [16].  Manufacturers of contrast media do not 
specify the free and bound proportions of iodide used in their product sheets, and the amount of 
free iodide is likely to vary between and within manufacturers [14,27].  A single dose of Omnipaque 
contrast media (with a small application of topical iodine for skin cleansing) was estimated to expose 
an infant to 243 g/kg of free iodide [14].  Another study reported a content range, for various 
media (including Omnipaque), of 2-21 g/ml [27].  Precise information about the actual dose of free 
iodide that an infant is exposed to is further confused by the in vivo degradation of iodide, which 
increases the biological load.  The most commonly used contrast media in our cohort was Ultravist 
300 at a modal dose of 0.3ml i.e. 90mg of iodine.  If we assume 21 g/ml [27] is representative of 
the free iodide content of the contrast media used in our study, it suggests that our infants were 
exposed to about 6 g/iodide per dose, which could explain why so few of the infants showed 
marked thyroid dysfunction.  
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Quantitative information about the free iodide content of topical iodine solutions is also not readily 
available.  Furthermore, although the placenta can store iodine and perhaps protect the fetus from 
deficiency [28], is it is not clear how infants become exposed to iodide from caesarean section 
and/or epidural anaesthesia.  It could be via the blood directly, as iodide also crosses the placenta 
[22], but a more substantive source is likely to be breast milk, as iodide is actively concentrated in 
the breast [29].   
Monitoring exposed infants will undoubtedly reveal high levels of urinary iodide [21], but increased 
levels do not establish definitive proof that the thyroid gland has been adversely affected.  The 
assays measuring urinary iodine cannot distinguish between bound iodide and free iodide, and it is 
only the latter that is taken up by the thyroid gland [30].  Furthermore comparatively few infants 
exposed to iodine and with high levels of urinary iodide, actually exhibit thyroid dysfunction [15].  
There are many other unknown facts.  For instance, the relationship between urinary/serum iodide 
levels and thyroid function is unclear; infants exposed to the same quantities and types of contrast 
media show different thyroid responses and urinary iodide levels; and, exposure to contrast media 
and/or topical iodine can raise urinary iodine levels >1000-fold yet remarkably few exposed infants 
show thyroid dysfunction [15].  Because of this ambiguity, we elected not to measure urinary/serum 
iodide levels in our exposed infants.  We assumed that iodine exposure had occurred based on the 
circumstantial evidence provided by the previous research [13-15], and the cautionary notes of the 
contrast media manufacturers and BNF [23].   
Our findings are generally quite different from those reported previously [9-11,14,19,29] and from 
the conclusions drawn by systematic reviews of exposure via contrast media [20] and povidone-
iodine [21].  How authors define and measure thyroid dysfunction may explain some of the disparity 
between studies.  Many authors either omit a definition or describe hypothyroidism using only 
clinical terminology [9,10,18]; others imply use of a quantified cut-off [14,15,19,29]; but very few set 
out a clear definition in their methods [17].  Recent guidelines [31] state that venous TSH levels 
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>20mU/L, with or without low, age-adjusted, FT4 levels, should be the threshold for thyroxine 
treatment.  As TSH levels in whole blood are about one-half those in serum, it maybe that our 
definition of hyperthyrotropinaemia is unduly strict and will under report infants with thyroid 
dysfunction.  We did not measure FT4, although we did have (total) T4 measurements.  However 
interpretation of neonatal T4 measurements, especially in a preterm population, is complex – 
affected by the ontogeny of thyroid hormones, time of testing [32], sickness levels, the action of 
drugs such as dopamine, dexamethasone and caffeine [18,26,33] and lack of reference range data 
for whole blood measurements.  Using the T4 z score provided by the screening laboratory helps a 
little, as it is calculated on a daily basis and reflects the population sampled on that day.  
Nevertheless, preterm infants by the nature of their preterm birth are going to fall in the far left of 
the distribution curve.  Our definition of hypothyroidism, however, reflected clinical practice as we 
classified hypothyroidism pragmatically on the basis of requiring Levo-Thyroxine treatment, and 
units followed their routine clinical protocols guided by locally taken and analysed thyroid function 
tests.   
Our study has several strong features.  With the exception of screening recall studies, our study is 
the largest, gestational-age relevant, prospective case-comparison study undertaken.  It uses a 
contemporary population and adjusted for the key potential confounding influences of TSH, such as 
drug usage and illness.  Our definition of thyroid function was agreed a priori.  Infants were followed 
for 28 days postnatally and then again at the equivalent of 36 weeks’ gestation. The gap between 
neonatal thyroid monitoring and the equivalent of 36 weeks’ gestation is, by definition, greater the 
earlier the gestational age at birth i.e. the very infants who are at most risk of thyroid dysfunction 
due to exposure.  It is possible that the confirmatory normal TSH levels at 36 weeks’ gestation which 
were found for all infants, masked transitionally high TSH levels during the weeks when no 
measurements were undertaken.    
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Our study has some limitations.  We have assumed iodine exposure occurred.  The contrast media 
and topical iodine used in our study hospitals have been reported in other studies to be associated 
with greatly elevated urinary iodide levels and, in the absence of any change in manufacture, we 
believe the infants in our study will also have been exposed to similar levels of free and bound 
iodide. Our study has an element of recruitment bias; although we aimed for consecutive 
recruitment, some infants were missed and our population was skewed to the older gestations, 
which has the effect of attenuating any relationship between iodine exposure and neonatal thyroid 
outcome.   We estimate that we might have missed 40% of eligible infants, so even if all the missed 
infants had thyroid dysfunction we would still report an incidence of well below the 78-80% 
reported previously [14].  Our exposure source was biased towards contrast media, with relatively 
few infants exposed to topical iodine.  While we collected information about drug usage that may 
affect levels of TSH and thyroid hormones, we did not collect any information about renal function, 
impairment of which can affect clearance of iodine which may in turn impact the risk of developing 
hypothyroidism.   
The BNF cautions against the use of topical iodine in preterm infants and in women during 
pregnancy and breast feeding, and manufacturers of contrast media recommend monitoring thyroid 
function after administration because of the risk of hypothyroidism due to iodine overload.  The use 
of contrast media for neonates is widespread and one study reported its use in 64% of UK neonatal 
units [34].  The use of topical iodine is not well recorded and its use in UK neonatal units has possibly 
decreased from around 21% in 2006 [21] to 1% in 2013 [35] as units move to chlorhexidine 
gluconate for skin antisepsis.  Use of topical iodine in obstetric units is also poorly recorded and one 
survey found it was used in 57% of obstetric units [21].  However, obstetric and neonatal surgical 
applications of topical iodine is likely to be more harmful to the preterm infant than neonatal skin 
cleansing prior to catheter placements, because the quantity of topical iodine used per application 
for skin cleansing prior to caesarean section or epidural or neonatal surgery is much greater than for 
neonatal catheter positioning.   
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From the results of this study it is not possible to say unequivocally that exposure causes no harm; 
although the incidence of thyroid dysfunction as a result of exposure to iodinated contrast media is 
very unlikely to be near the high level reported by L’Allemand et al [14].  But, even with our perhaps 
over strict definition of thyroid dysfunction, several infants in our study had transient thyroid 
dysfunction, which is associated with neurodevelopmental compromise [34].  The best evidence to 
date is from the systematic reviews which indicate that neonatal thyroid dysfunction is present in 
around 18-20% of exposed infants [20,21].  A randomized controlled trial is needed to determine 
unequivocally whether exposure to extraneous iodine causes thyroid dysfunction.  In the meantime, 
clinicians can debate or act on the advice of the BNF [23], the American Pharmacists Association 
[24], and the manufacturers of contrast media. (Chlorhexidine or octenidine are alternatives to 
topical iodine, although also hold risks for preterm infants [36].)  However, until research is 
unequivocal it is imperative that all preterm infants exposed to extraneous iodine have their thyroid 
function monitored, for a sufficient period as per the manufacturers’ advice, post exposure.  Clinical 
guidelines, which define cut-offs for normal TSH and (F)T4 levels, and which are relative to the 
gestational and postnatal age of the infant and the blood media used, are a priority. 
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TABLE 1 SOURCES OF NEONATAL EXPOSURE TO IODINE  
 
Sources of iodine exposure 
Single exposure source 
 
 Neonatal contrast media 
 Topical iodine prior to caesarean section 
 
 
N=95 
N=16 
Mixed exposure source 
 
 Maternal use of vitamins containing iodine and neonatal 
contrast media 
 Topical iodine prior to caesarean section and neonatal 
contrast media 
 Neonatal use of iodine based eye-drops and possible 
maternal vitamins containing iodine use 
 
 
 
N=9 
 
N=4 
 
N=1 
Unexposed N=48 
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TABLE 2 ROUTES*OF EXTRANEOUS IODINE EXPOSURE, GESTATIONAL AGE, POSTNATAL TSH AND T4 LEVELS AND DATE OF DEATH IN INFANTS WHO 
RECORDED TSH LEVELS ≥6MU/L 
 
C/S caesarean section   C-M contrast media for placement of central venous catheters    
*  No infant was exposed to iodine for skin disinfectant prior to placement of long line or surgery  
**36 weeks refers to the week of gestation that the preterm infant would have been in had they remained in utero  
 
Infant Gestation 
(weeks + day) 
Route and 
day of 
exposure 
TSH mU/L 
day 7 
T4 z score 
day 7 
TSH mU/L 
day 14 
T4 z score 
day 14 
Route and 
day of 
exposure 
TSH mU/L 
day 28 
T4 z score 
day 28 
TSH mU/L 
36 weeks** 
T4 z score 
36 weeks** 
Week of death 
if applicable 
1 28 + 5 C/S 8 -2.1 3 -1.8  5 -2.4 4 -1.7 n/a 
2 29 + 1 C/S 6 -1.4 7 -2.5  7 -1.4 missing missing n/a 
3 28 + 6 C-M d3 10 -3.1 2 -2.1  11 -3.4 4 -2.9 n/a 
4 31 + 2 C-M d6 9 -3.3 3 -1.9  4 -1.8 4 -1.3 n/a 
5 30 + 1 C/S 2 -2.5 7 -2.1  2 -2.5 2 -1.8 n/a 
6 24 + 6 C-M d3 1 -3.8 8 -2.7 C-M d17 1 -3.0 n/a n/a Equivalent of 32 
weeks’ gestation 
7 27 + 4 C-M d3 1 -3.2 10 -2.4  5 -3.9 4 -1.7 n/a 
8 28 + 0 C-M d2&3 1 -3.8 25 -3.2 C-M d20 1 -3.0 3 -2.4 n/a 
9 29 + 5 C-M d0 3 -2.4 6 -2.8  missing missing missing missing n/a 
Unexposed infants   
1 31 + 1  2 -1.2 8 -1.3  2 -1.9 2 0.4 n/a 
2 28 + 0  2 -2.0 6 -1.9  2 -1.9 2 -1.2 n/a 
3 30 + 2  4 -2.2 5 -2.5  6 -2.5 4 -1.3 n/a 
4 31 + 1  1 -2.0 1 -2.3  6 -1.2 1 -1.6 n/a 
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TABLE 3 INFANT AND MATERNAL CHARACTERISTICS    
 EXPOSED 
caesarean section  contrast media Mixed exposure 
only N=16 only N=95 N=14 
UNEXPOSED 
 
N=48 
 Mean   (SD) Mean     (SD) Mean     (SD) Mean      (SD) 
Gestation (weeks)  29.6  (1.5)  28.2 (1.9) a  27.1 (2.6)aa  29.2  (2.0) 
Birth weight (g) 1437  (329)  1154 (326)b  948 (262)bb  1329 (333) 
Birthweight ratio  1.1 (0.2)  1.0 (0.2)  0.9 (0.2)  1.0 (0.2) 
Maternal thyroid disease  
 Yes 0 
 No 16 (100%) 
 missing data 0 
 
   7 (7%) 
 85 (90%) 
   3 (3%) 
 
 0 
 13 (93%) 
   1 (7%) 
 
   3 (6%) 
 43 (90%) 
   2 (4%) 
Nutrition on day 7 
 breast milk (ml) 
 formula milk (ml) 
 total (ml) 
Nutrition on day 14 
 breast milk (ml) 
 formula milk (ml) 
 total (ml) 
 missing data  
Nutrition on day 28 
 breast milk (ml) 
 formula milk (ml) 
 total (ml) 
 missing data  
Mean    (SD) 
143 (92) 
62 (79) 
216 (45) 
 
174 (133) 
89 (121) 
263 (54) 
 
 
127 (162) 
198 (163) 
325  (73) 
2 
Mean        (SD) 
 52 (59) 
 3 (18) 
 170 (54) 
 
 116 (93) 
 15 (44) 
 185 (55) 
 3 
 
 176 (114) 
 34 (84) 
 236 (70) 
 7 
Mean       (SD) 
 48 (98) 
 17 (43) 
 160 (95) 
 
 80 (78) 
 41 (82) 
 147 (43) 
  
 
 91 (84) 
 74 (120) 
 177 (65)  
Mean       (SD) 
 104 (99) 
 44 (77) 
 198 (56) 
 
 126 (112) 
 71 (102) 
 216 (59) 
 2 
 
 129 (131) 
 133 (150) 
 268 (78) 
 10 
Gender 
 female 
 male 
 
7 (44%) 
9 (56%)  
 
48 (51%) 
47 (49%) 
 
5 (36%) 
9 (64%) 
 
18 (38%) 
30 (63%) 
Caffeine day 7 
 yes 
 no 
Caffeine day 14 
 yes 
 no 
 died 
Caffeine day 28 
 yes 
 no 
 died 
 missing data 
 
6 (38%)c 
10 (63%) 
 
3 (19%)d 
13 (81%) 
 - 
 
1 (6%) 
15 (94%) 
- 
- 
 
81 (85%) 
14 (15%)  
 
83 (87%)dd 
10 (11%) 
2 (2%) 
 
55 (58%)e 
35 (37%) 
  3 (3%) 
2 (2%) 
 
11 (79%) 
3 (21%) 
 
12 (86%) 
2 (14%) 
 
 
8 (57%) 
6 (43%) 
- 
- 
 
34 (71%) 
14 (29%) 
 
25 (52%) 
21 (44%) 
2 (4%) 
 
13 (27%) 
30 (63%) 
  3 (6%) 
2 (4%) 
a compared to unexposed t=2.87, p=0.005   aa compared to unexposed t=2.79, p=0.013 
b compared to unexposed t=3.00, p=0.003   bb compared to unexposed t=4.49, p=0.0001 
c compared to unexposed, Fisher exact p=0.04 d compared to unexposed, Fisher exact p=0.03     
dd compared to unexposed, Fisher exact p=0.00002  e compared to unexposed, Fisher exact p=0.002 
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TABLE 4 DIFFERENCES IN MEAN LEVELS OF TSH AND T4 IN HEEL PRICK BLOOD ON POSTNATAL DAYS 7, 14 AND 28 AND EQUIVALENT OF 36 WEEKS’ 
GESTATION ACCORDING TO SOURCE OF EXPOSURE  
 Caesarean section only Contrast media only Mixed exposure Unexposed 
 day 7 day 14 day 28 36 wks day 7 day 14 day 28 36 wks day 7 day 14 day 28 36 wks day 7 day 14 day 28 36 wks 
TSH  mean 
mU/L s.d. 
 n sampled 
n available* 
2.87 a 
2.03 
15 
16 
3.19 a 
1.80 
16 
16 
3.14 a  
1.66 
14 
14 
2.13 
1.13 
8 
14 
1.50  
1.39 
88 
95 
1.98  
2.86 
90 
93 
1.67  
1.47 
81 
92 
1.72  
1.05 
74 
92 
1.83 
1.03 
12 
14 
1.43  
1.09 
14 
14 
1.86  
1.17 
14 
14 
2.0 
1.0 
9 
14 
1.69 
0.97 
45 
48 
2.07  
1.61 
44 
46 
1.87  
1.32 
38 
42 
1.71 
0.89 
35 
42 
                 
T4  mean 
nmol/L s.d. 
 n sampled 
n available* 
44b 
9.5 
15 
16 
52b 
17.2 
16 
16 
48 
10.4 
14 
16 
59 
18.0 
8 
16 
32   
12.5 
88 
95 
39 
14.4 
90 
93 
43 
13.7 
81 
92 
51 
12.9 
74 
92 
29 
15.1 
12 
14 
36 
16.4 
14 
14 
31c 
15.7 
14 
14 
58 
13.6 
9 
14 
33 
12.0 
45 
48 
40 
12.9 
44 
46 
42 
14.2 
38 
42 
51 
20.1 
35 
42 
                 
a TSH levels caesarean section only compared to TSH levels unexposed: day 7 p=0.05, day 14 p=0.04, day 28 p=0.02 
b T4 levels caesarean section only compared to T4 levels unexposed: day 7 p=0.001, day 14 p=0.02 
c T4 levels mixed exposure compared to T4 levels unexposed: day 28 p=0.03 
* the denominator of ‘n available’ takes into acccount the 6 infant deaths and 3 infants discharged, and the age at death/discharge  
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TABLE 5 REGRESSION ANALYSES OF EXPOSURE TO IODINE ON TSH LEVELS ADJUSTED* FOR 
CONFOUNDING VARIABLES 
TSH level on day 7 Effect estimate Standard error t P value 
Iodine exposure group 
Caesarean section only 
Mixed exposure 
Contrast media only 
unexposed 
 
0.888 
-0.042 
-0.313 
 reference 
 
0.277 
0.312 
0.168 
 
3.203 
-0.134 
-1.859 
 
0.002 
0.894 
0.065 
Nursing level of care 
Level 1 (highest level) 
Level 2 and 3 (moderate/low) 
 
-0.314 
 reference 
 
0.212 
 
-1.482 
 
0.141 
Caffeine prescribed on day 7 
Yes 
No 
 
0.066 
 reference 
 
0.179 
 
0.370 
 
0.712 
Infant gender 
Male 
Female 
 
-0.178 
 reference 
 
0.143 
 
-1.250 
 
0.213 
Gestational age -0.023 0.047 -0.485 0.628 
Birth weight ratio -1.265 0.418 -3.030 0.003 
TSH level on day 14     
Iodine exposure group 
Caesarean section only 
Mixed exposure 
Contrast media only 
unexposed 
 
1.745 
-1.360 
-0.640 
 reference 
 
0.800 
0.874 
0.523 
 
2.182 
-1.556 
-1.224 
 
0.031 
0.122 
0.223 
Nursing level of care 
Level 1 (highest level) 
Level 2 and 3 (moderate/low) 
 
1.338 
 reference 
 
0.704 
 
1.902 
 
0.059 
Caffeine prescribed on day 14 
Yes 
No 
 
0.845 
 reference 
 
0.567 
 
1.491 
 
0.138 
Infant gender 
Male 
Female 
 
-0.029 
 reference 
 
0.403 
 
-0.072 
 
0.943 
Gestational age 0.066 0.138 0.475 0.636 
Birth weight ratio -1.473 1.188 -1.240 0.217 
TSH level on day 28     
Iodine exposure group 
Caesarean section only 
Mixed exposure 
Contrast media only 
unexposed 
 
1.282 
-0.572 
-0.252 
 reference 
 
0.365 
0.384 
0.231 
 
3.509 
-1.490 
-1.089 
 
0.001 
0.139 
0.278 
Nursing level of care 
Level 1 (highest level) 
Level 2 and 3 (moderate/low) 
 
-0.594 
 reference 
 
0.372 
 
-1.596 
 
0.113 
Caffeine prescribed on day 28 
Yes 
No 
 
-0.330 
 reference 
 
0.237 
 
-1.393 
 
0.166 
Infant gender 
Male 
Female 
 
0.007 
 reference 
 
0.186 
 
0.040 
 
0.968 
Gestational age -0.203 0.074 -2.722 0.007 
Birth weight ratio -1.839 0.557 -3.303 0.001 
 *  Dexamethasone and dopamine usage were not used in the regression model as so few 
infants received these drugs. 
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